Zacks Investment Research on MSN
Can Bristol Myers' growth portfolio offset legacy drug declines?
Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the ...
Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...
Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...
The cost of Opdivo Qvantig can vary based on several factors, including your insurance coverage. Drug savings programs can help to lower the price you’ll pay for Opdivo Qvantig. As with all ...
Ono Pharma submits supplemental application in Japan to expand the Use of Opdivo to treat unresectable anaplastic thyroid cancer: Osaka, Japan Friday, June 12, 2026, 09:00 Hrs [IS ...
Bristol-Myers Squibb ($BMY) has gotten more bad news in its efforts to grow lung cancer sales. England's cost watchdog has turned it down, although the regulator did ...
7d
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
Earlier this week, the European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with AVD ...
InvestorsHub on MSN
Bristol Myers Squibb wins EU green light for Opdivo-based Hodgkin lymphoma treatment (BMY)
Bristol Myers Squibb (NYSE:BMY) has secured approval from the European Commission for the use of Opdivo (nivolumab) in ...
* Opdivo was approved to treat esophageal cancer in 2020. The guidelines are from 2019 and haven’t been updated to make a recommendation for Opdivo. †For liver cancer, Keytruda is listed as “under ...
Bristol Myers Squibb Co (NYSE:BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or ...
Opdivo failed to improve PFS in PD-L1—positive NSCLC patients compared to standard chemotherapy in the CheckMate-026 study. Keytruda showed better outcomes in similar settings, highlighting a ...
Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results